独立董事 2024 年度述职报告 （曲新） 乐普（北京）医疗器械股份有限公司 独立董事述职报告 乐普（北京）医疗器械股份有限公司 本人作为乐普（北京）医疗器械股份有限公司（以下简称"公司"）的独立 董事，2024 年度任职期间严格按照《公司法》《证券法》《上市公司独立董事 管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等相关法律法规和《公司章程》《独立董事工作制度》等公司相关的 规定和要求，忠实履行独立董事的职责，充分发挥独立董事独立性和专业性的作 用，维护了全体股东尤其是中小股东的合法权益。现将本人 2024 年度履行独立 董事职责情况向各位董事汇报如下： 一、独立董事基本情况 1963 年出生，中国国籍，无境外永久居留权，财务管理研究员，高级会计 师，注册会计师。曾任中国新型建筑材料公司财务部综合处副处长、中国新型建 筑材料（集团）公司计划财务部副经理，中国建材集团有限公司财务部总经理。 现任中国企业改革发展研究会高级专家，华鹏飞股份有限公司独立董事、北京汉 仪创新科技股份有限公司独立董事、智慧互通科技股份有限公司（非上市公司） 独立董事。 本人未在公司担任除独立董 ...

前十大流通股东累计持有： 56055.46万股，累计占流通股比： 34.69%，较上期变化： -2236.36万股。 | 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 中国船舶重工集团公司第七二五研究所(洛阳船舶材料研 | | | | | 究所) | 24406.38 | 15.10 | 不变 | | 北京厚德义民投资管理有限公司 | 6775.00 | 4.19 | 不变 | | 蒲忠杰 | 5701.87 | 3.53 | 不变 | | 中国银行股份有限公司-华宝中证医疗交易型开放式指数 证券投资基金 | 4299.64 | 2.66 | -122.40 | | 宁波厚德义民投资管理有限公司 | 3585.00 | 2.22 | 不变 | | 中国工商银行股份有限公司-易方达创业板交易型开放式 指数证券投资基金 | 3376.46 | 2.09 | -17.49 | | WP MEDICAL TECHNOLOGIES, INC | 3099.22 | 1.92 | 不变 | | 中国农业银行股份 ...

Financial Performance - The company reported a decline in performance during the reporting period, with specific reasons and impacts detailed in the management discussion and analysis section [4]. - The company's operating revenue for 2024 was ¥6,103,269,105.88, a decrease of 23.52% compared to ¥7,979,899,319.74 in 2023 [18]. - The net profit attributable to shareholders for 2024 was ¥246,937,715.50, down 80.37% from ¥1,258,200,337.67 in 2023 [18]. - The net profit after deducting non-recurring gains and losses was ¥221,430,404.42, reflecting an 80.28% decline from ¥1,123,116,336.93 in 2023 [18]. - The net cash flow from operating activities decreased by 25.82% to ¥734,643,889.07 in 2024 from ¥990,359,814.31 in 2023 [18]. - The total assets at the end of 2024 were ¥24,573,100,199.19, a decrease of 1.80% from ¥25,022,331,486.69 at the end of 2023 [18]. - The net assets attributable to shareholders decreased by 4.85% to ¥15,201,421,378.82 at the end of 2024 from ¥15,976,101,963.31 at the end of 2023 [18]. - The company reported a basic earnings per share of ¥0.1336 for 2024, down 80.23% from ¥0.6757 in 2023 [18]. - The weighted average return on equity for 2024 was 1.59%, a decrease of 6.64 percentage points from 8.23% in 2023 [18]. Dividend Distribution - The company plans to distribute a cash dividend of 1.35 CNY per 10 shares (including tax) to all shareholders based on a total share capital of 1,843,395,382 shares after deducting repurchased shares [4]. - The company approved a cash dividend of RMB 3.3141 per 10 shares, totaling RMB 612,692,533.39 for the 2023 fiscal year [197]. - For the first half of 2024, the company declared a cash dividend of RMB 1.42 per 10 shares, amounting to RMB 261,762,075.23 [198]. - The total cash dividend for the year, including other methods, reached RMB 688,029,164.21, which is 138.07% of the distributable profit of RMB 498,312,992.38 [200]. - The cash dividend policy is compliant with the company’s regulations and has been clearly communicated to shareholders [199]. Research and Development - The company has applied for a total of 2,332 patents and has over 600 products registered domestically and internationally, including 670 medical device registrations approved by the National Medical Products Administration [101]. - R&D investment amounted to approximately ¥1.165 billion in 2024, representing 19.09% of the company's operating revenue, an increase from 15.56% in 2023 and 12.10% in 2022 [100]. - The company is focusing on the development of a continuous glucose monitoring system, which will provide comprehensive and reliable blood glucose information for diabetes management [100]. - The company is committed to the localization strategy of medical devices, aiming to make high-tech products affordable for a broader patient base [99]. - The company is focusing on four main areas of R&D innovation, including the integration of active devices with passive consumables, and the development of core products like cryoablation balloon systems and electric field ablation catheter systems [132]. Product Development and Innovation - The company is focusing on expanding its product pipeline in the cardiovascular and metabolic disease sectors, with several new products expected to be commercialized by 2025 [39]. - The company has launched several new cardiovascular interventional products, including coronary intravascular shockwave devices and biodegradable occluders [36][37]. - The innovative drug company under the company has completed Phase II clinical trials for the GLP-1/GCGR/GIP-Fc fusion protein candidate drug MWN101 [38]. - The company is actively exploring innovations in absorbable materials, biomaterials, and energy-driven technologies in its surgical anesthesia business [54]. - The company is focusing on developing products with clear clinical value and has established a compliance-driven sales system to mitigate risks associated with clinical needs and regulatory compliance [140]. Market Expansion and Strategy - The company aims to enhance its market position through innovation and internationalization strategies [32]. - The company has established a comprehensive overseas sales network covering over 160 countries and regions, with 213 products receiving EU CE certification [66]. - The international business is experiencing steady growth, supported by a dual strategy of channel cultivation and product diversification [66]. - The company is strategically shifting resources from generic drugs to innovative drugs and dermatological injection products to enhance long-term competitiveness [57]. - The company is focusing on self-funded medical products to mitigate the impact of domestic policy changes on performance [66]. Compliance and Governance - The company has committed to strict compliance with legal and regulatory requirements for information disclosure, publishing 4 regular reports and 121 temporary announcements during the reporting period [161]. - The company maintains a diverse board with members holding various leadership roles in other organizations, indicating strong industry connections [172]. - The company is focused on enhancing core competitiveness and risk management capabilities to achieve sustainable long-term development [151]. - The company has established a performance evaluation and incentive system linking the income of directors and senior management to business performance [160]. - The company is conducting regular compliance training to ensure adherence to legal requirements and improve overall operational integrity [140]. Challenges and Risks - Future development risks are highlighted in the report, indicating potential challenges the company may face [4]. - The company is facing risks from volume-based procurement policies affecting medical consumables and generic drugs, which may impact revenue and profit margins [139]. - The increasing number of competitors in the domestic innovative drug and medical device market may lead to price pressures, prompting the company to prioritize projects with strong commercial viability [145]. - The implementation of DRG/DIP payment methods is expected to limit the use of high-priced new products in hospitals, prompting the company to enhance its product pipeline and optimize production processes to maintain competitiveness [142]. - The company plans to adjust some overseas clinical research plans due to increased uncertainty from public health events and international conditions [122].

Financial Performance - The company's revenue for Q1 2025 was ¥1,736,231,253.08, a decrease of 9.67% compared to ¥1,922,028,839.15 in the same period last year[4] - Net profit attributable to shareholders was ¥378,539,846.83, down 21.44% from ¥481,871,134.58 year-on-year[4] - Total operating revenue decreased to ¥1,736,231,253.08 from ¥1,922,028,839.15, representing a decline of approximately 9.66% year-over-year[27] - Net profit for the period was ¥377,214,013.29, down from ¥492,760,543.46, indicating a decrease of approximately 23.36%[28] - Operating profit decreased to ¥468,447,639.53 from ¥609,221,198.42, reflecting a decline of around 23.1%[28] - Basic earnings per share decreased to ¥0.2053 from ¥0.2594, a drop of approximately 20.9%[29] - The company reported a total comprehensive income of ¥389,042,851.43, down from ¥483,962,303.22, a decrease of approximately 19.6%[28] Cash Flow - The net cash flow from operating activities increased by 196.09% to ¥419,022,240.55, compared to ¥141,518,257.63 in the previous year[4] - Cash flow from operating activities increased significantly to ¥419,022,240.55 from ¥141,518,257.63, marking an increase of about 195.5%[29] - The net cash flow from investing activities was -464,047,420.78, compared to -280,016,903.64 in the previous period, indicating a significant increase in cash outflow for investments[30] - The total cash inflow from financing activities was 854,168,158.32, up from 646,677,567.42, reflecting a strong increase in financing received[30] - The net cash flow from financing activities was 82,162,782.14, a turnaround from -52,062,147.66 in the previous period, showing improved financial health[30] - The company reported a cash increase of 38,471,234.23, contrasting with a decrease of -188,896,639.47 in the previous period, suggesting a recovery in cash position[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥25,233,363,806.46, reflecting a 2.69% increase from the previous year[4] - The company's total liabilities increased to CNY 8,074,135,866.99 from CNY 7,832,663,884.27, representing a rise of about 3.09%[25][26] - The total equity attributable to shareholders rose to CNY 15,615,828,015.50, up from CNY 15,201,421,378.82, indicating an increase of approximately 2.73%[26] - Cash and cash equivalents at the end of the period were CNY 3,729,685,667.04, slightly up from CNY 3,718,016,911.13, showing a marginal increase of 0.46%[24] - Accounts receivable increased significantly to CNY 1,857,183,008.74 from CNY 1,530,657,231.48, marking a growth of approximately 21.31%[24] - Inventory decreased to CNY 1,977,616,736.79 from CNY 2,030,235,942.18, reflecting a decline of about 2.59%[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 94,228[16] - The largest shareholder, China Shipbuilding Industry Group, holds 12.98% of shares, totaling 244,063,788 shares[16] - Shareholder Pu Zhongjie holds 12.13% of shares, totaling 228,074,749 shares, with 171,056,062 shares pledged[17] - WP Medical Technologies, Inc. holds 6.59% of shares, totaling 123,968,600 shares, with 92,976,450 shares pledged[17] - The top ten shareholders account for significant portions of the company's equity, with the largest holding being 12.98%[16] - The company has a total of 171,056,062 restricted shares held by Pu Zhongjie, which are subject to management lock-up[20] Investment and R&D - The company plans to continue focusing on research and development, with R&D expenses increasing to ¥203,326,022.08 from ¥197,385,261.91, an increase of about 3.5%[27] - The company's long-term investments in equity increased to CNY 1,212,784,329.49 from CNY 1,189,771,189.43, a growth of approximately 1.12%[24] Financial Expenses - Financial expenses rose to ¥33,282,300, a significant increase of 3,726.23% year-on-year, primarily due to foreign exchange losses[10] - Cash paid for debt repayment was 682,000,000.00, compared to 478,000,000.00 previously, indicating a higher commitment to servicing debt[30] - Cash paid for dividends and interest was 51,814,597.34, up from 38,686,008.93, reflecting an increase in shareholder returns[30]

2024 年 12 月，财政部发布《企业会计准则解释第 18 号》（财会〔2024〕 24 号），规定对不属于单项履约义务的保证类质量保证产生的预计负债，应当按 确定的金额计入"主营业务成本"、"其他业务成本"等科目，该解释规定自印发 之日起施行，允许企业自发布年度提前执行。 由于上述会计准则解释的发布，公司需对会计政策进行相应变更，并自上述 文件规定的生效日期起执行上述会计准则。 （二）变更前采用的会计政策 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次会计政策变更情况概述 （一）变更的原因 2023 年 10 月，财政部发布《企业会计准则解释第 17 号》（财会〔2023〕 21 号），规定了"关于流动负债与非流动负债的划分"、"关于供应商融资安排的 披露"、"关于售后租回交易的会计处理"的相关内容，该解释规定自 2024 年 1 月 1 日起施行。 证券代码：300003 证券简称：乐普医疗 公告编号：2025-030 乐普（北京）医疗器械股份有限公司 关于会计政策变更的公告 本次变更前，公司执行财政部发布的《企业会计准则—基本准则》和各项具 ...

乐普（北京）医疗器械股份有限公司 证券代码：300003 证券简称：乐普医疗 公告编号：2025-014 乐普（北京）医疗器械股份有限公司2024年年度报告全文及报告摘要于2025 年 4 月 19 日 在 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露，敬请投资者注意查阅。 特此公告。 2024 年年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 乐普（北京）医疗器械股份有限公司 董事会 二○二五年四月十九日 ...

董事会 二〇二五年四月十九日 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 等要求，乐普（北京）医疗器械股份有限公司（以下简称"公司"）董事会就公 司在任独立董事的独立性情况进行评估并出具如下专项意见： 经核查，公司独立董事甘亮先生、王立华先生、曲新女士未在公司担任除独 立董事以外的任何职务，也未在公司主要股东公司担任任何职务，与公司及主要 股东之间不存在利害关系或其他可能妨碍其进行独立客观判断的关系，不存在其 他影响独立董事独立性的情况，因此，公司独立董事符合《上市公司独立董事管 理办法》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规 范运作》等法律法规及《公司章程》中对独立董事的任职资格及独立性的相关要 求。 乐普（北京）医疗器械股份有限公司 乐普（北京）医疗器械股份有限公司 董事会关于独立董事独立性情况的专项意见 ...

关于乐普（北京）医疗器械股份有限公司2024年度募集资 金存放与使用情况 专项报告的鉴证报告 关于乐普（北京）医疗器械股份有限公司 2024 年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第 ZG11562 号 乐普（北京）医疗器械股份有限公司 募集资金存放与使用情况 鉴证报告 | 目 | 录 | 页 | 次 | | --- | --- | --- | --- | | 一、募集资金年度存放与使用情况鉴证报告 | 1-3 | | | | 二、2024 | 年度募集资金存放与实际使用情况的专项报告 | 4-11 | | | 三、附表一：募集资金使用情况对照表 | 12-13 | | | | 附表二：境外公开发行GDR项目募集资金使用情况对照表 | 14 | | | 信会师报字[2025]第ZG11562号 乐普（北京）医疗器械股份有限公司全体股东： 我们接受委托，对后附的乐普（北京）医疗器械股份有限公司（以 下简称"乐普医疗"）2024年度募集资金存放与使用情况专项报告（以 下简称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 乐普医疗公司董事会的责任是按照中国证券监督 ...

乐普（北京）医疗器械股份有限公司 2024 年度财务决算报告 证券代码：300003 证券简称：乐普医疗 公告编号：2025-013 乐普（北京）医疗器械股份有限公司 2024 年度财务决算报告 2025 年 4 月 乐普（北京）医疗器械股份有限公司 2024 年度财务决算报告 报告期末，公司按照《企业会计准则》及《深圳证券交易所股票上市规则》的相关 要求对 2024 年度存在减值迹象的资产以及对所有投资形成的商誉进行系统性减值测 试，并聘请独立的专业评估机构针对特定公司进行评估，绝大部分企业，特别是几个 大型企业经营状况良好，无计提减值的风险。基于公司的审慎评估，商誉和其他特定 资产共发生减值损失合计 25,128.08 万元，其对归属于上市公司股东的净利润的影响 为 21,666.94 万元。主要包括：收购苏州博思美形成的商誉净额为 8,910.17 万元，计 提减值准备 5,928.22 万元，收购乐普装备形成的商誉为 934.28 万元，计提减值准备 366.56 万元；公司的应急产品存货经过审慎评估，计提减值准备 13,575.09 万元；公 司自研的新冠 POCT 无形资产计提减值准备 1,578 ...

Core Viewpoint - The percutaneous coronary intervention (PCI) market in China is experiencing significant growth due to increasing rates of cardiovascular diseases driven by aging population and rising obesity rates, with the number of PCI procedures expected to reach 3.6 million by 2030 from 1.9 million in 2024 [1][11]. Industry Overview - PCI is a minimally invasive procedure aimed at improving blood flow in narrowed or blocked coronary arteries, with various techniques including balloon angioplasty and stent implantation [1][5]. - The PCI industry is supported by a supply chain that includes raw materials like stainless steel and cobalt-chromium alloys, as well as advanced medical devices and technologies [5]. Industry Environment - China has approximately 330 million patients with cardiovascular diseases (CVD), with a significant portion being elderly, which correlates with a rising incidence of heart diseases [7]. - The aging population in China is projected to increase from 145 million in 2015 to 220 million by the end of 2024, leading to a higher prevalence of cardiovascular diseases [7]. Industry Status - The total number of registered PCI cases in China reached 1,636,055 in 2023, marking a year-on-year growth rate of 26.44%, the highest recorded [9]. - National policies are enhancing healthcare services and infrastructure, leading to increased accessibility and acceptance of PCI procedures among patients [11]. Development Trends - The PCI industry is witnessing rapid technological innovation and product upgrades, with advancements in drug-eluting stents and biodegradable stents improving treatment outcomes and reducing complications [20]. - Market demand for PCI is expected to continue growing due to rising cardiovascular disease rates and increased public awareness of health [21]. - The industry faces intensified international competition, necessitating domestic companies to enhance innovation and expand into global markets [22]. Competitive Landscape - The PCI market in China is characterized by a mix of international giants like Medtronic and Abbott, and domestic companies such as Lepu Medical and Sino Medical, with the latter gaining market share through competitive pricing and innovative products [15][16]. - Companies like Weimai Medical and Yiju Medical are focusing on comprehensive solutions in interventional devices, with a strong emphasis on research and development [16][18].